Physician profile
John L Scheitler
NPI 1093786360
$15,397.88
in general payments reported to CMS, 2019-2025
77 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $1,344 · 2021: $2,239 · 2022: $2,804 · 2023: $2,306 · 2024: $2,512 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,075 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,075.47 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,390.32 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,210.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,197.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Supernus Pharmaceuticals, INC. | $1,183.83 | 2019-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $1,025.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $890.53 | 2019-2025 | |
| Amgen INC. | $805.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $709.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $522.90 | 2019-2025 | Bexsero, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $454.64 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $377.41 | 2019-2025 | Trintellix, Gattex |
| Merck Sharp & Dohme LLC | $366.32 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Aytu Biopharma, INC. | $339.82 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.54 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $317.09 | 2019-2023 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Scheitler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.